Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “mHSPC”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT05241860
What this trial is testing

Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM)

Who this might be right for
Castration-Sensitive Prostate CarcinomaMetastatic Prostate CarcinomaStage IV Prostate Cancer AJCC v8+2 more
Alliance for Clinical Trials in Oncology 79
Large-scale testing (Phase 3)Study completedNCT04736199
What this trial is testing

Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer

Who this might be right for
Prostatic Neoplasms
Bayer 669
Not applicableLooking for participantsNCT07172685
What this trial is testing

Study on Triple Therapy Combined With HIFU for High-Tumor-Burden mHSPC

Who this might be right for
Prostate Cancer
Qilu Hospital of Shandong University 116
Not applicableLooking for participantsNCT06334809
What this trial is testing

INSIDE: Identification of Genomic Screening Pathways in Cancer Patients With DNA Repair Alterations

Who this might be right for
Prostate Cancer
Fondazione del Piemonte per l'Oncologia 400
Not applicableLooking for participantsNCT06446401
What this trial is testing

The Case of "Triple" Versus "Double" Therapy for Patients With High Volume Metastatic Hormone Sensitive Prostate Cancer

Who this might be right for
Prostate Cancer
Uppsala University 1,400
Very early researchLooking for participantsNCT05713578
What this trial is testing

Efficacy and Safety of Apantamide Combined With Docetaxel and ADT vs. Apantamide Combined With ADT in Patients With High Tumor Burden mHSPC: a Multicenter and Prospective Cohort Study

Who this might be right for
Cohort Studies
Qilu Hospital of Shandong University 220
Early research (Phase 1)Active Not RecruitingNCT06193993
What this trial is testing

Effect of Low-dose 500 mg Abiraterone Acetate in Treatment of Metastatic Prostate Cancer Patients

Who this might be right for
Prostate CancerMetastatic CancerHormone Sensitive Prostate Cancer+1 more
National University Hospital, Singapore 10
Not applicableLooking for participantsNCT07451002
What this trial is testing

Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in France

Who this might be right for
Prostatic NeoplasmsMetastatic Hormone-sensitive Prostate Cancer
Janssen Cilag S.A.S. 540
Large-scale testing (Phase 3)Not Yet RecruitingNCT07711002
What this trial is testing

Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
AstraZeneca 1,330
Not applicableStudy completedNCT06452212
What this trial is testing

Non-Interventional Study to Establish Consensus on Management of Metastatic Hormone-Sensitive Prostate Cancer Patients

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer
Astellas Pharma Korea, Inc. 23
Large-scale testing (Phase 3)Active Not RecruitingNCT05288166
What this trial is testing

Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Who this might be right for
Prostatic NeoplasmsNeoplasm MetastasisUrogenital Neoplasms+14 more
Eli Lilly and Company 925
Testing effectiveness (Phase 2)WithdrawnNCT03343977
What this trial is testing

Toxicity & Pharmacokinetics of 2 & 3-weekly Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer
Peng Wang, MD PhD
Testing effectiveness (Phase 2)Study completedNCT06312670
What this trial is testing

Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)Prostate CancerProstate Adenocarcinoma
Pedro Barata, MD, MSc 13
Very early researchActive Not RecruitingNCT05683964
What this trial is testing

Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression

Who this might be right for
Prostate AdenocarcinomaProstate CancerMetastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Beth Israel Deaconess Medical Center 9
Early research (Phase 1)Looking for participantsNCT07140900
What this trial is testing

Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Amgen 60
Testing effectiveness (Phase 2)UnknownNCT05167175
What this trial is testing

The Study of Olaparib Combined With Abiraterone and Prednisone in mHSPC Patients With HRR Gene Mutation

Who this might be right for
Prostate CancerProstate CarcinomaMetastatic Prostate Cancer
Hongqian Guo 30
Testing effectiveness (Phase 2)Study completedNCT05059236
What this trial is testing

Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer
Bayer 223
Large-scale testing (Phase 3)Study completedNCT04934722
What this trial is testing

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer
Merck Sharp & Dohme LLC 186
Not applicableActive Not RecruitingNCT06019676
What this trial is testing

Impact of Apalutamide in Metastatic Hormone Sensitive Prostate Cancer Patients

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Royal Marsden NHS Foundation Trust 170
Not applicableStudy completedNCT07428642
What this trial is testing

PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.

Who this might be right for
Metastatic Hormone-Sensitive Prostate CancerProstate Cancer
First Affiliated Hospital of Wenzhou Medical University 168
Next Page